The reduction in tumor immune cells upon MEK inhibition or SHP2 inhibition at 10 mg/kg was accounted for largely by a twofold reduction in tissue macrophages, a trend toward a reduction in DCs, and a reduction in monocytes (Fig 3B). Here, PTPN11 is linked to neoplasm.